BCG Vaccines for Cancer

Taking advantage of animal and immunologic studies that defined optimal conditions for BCG response, urologists have developed BCG into the most effective treatment currently available in the treatment of aggressive superficial bladder cancer. A number of cancer vaccines use BCG as an additive to provide an initial stimulation of the person's immune systems. Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best development services for BCG vaccines in cancer treatment. We guarantee the finest results for our customers all over the world.

BCG in Bladder Cancer

BCG is a live attenuated vaccine of Mycobacterium bovis that was initially developed in the early 1900s as a vaccine against tuberculosis. It was later observed that patients with tuberculosis actually had lower rates of cancer and subsequently hypothesized that mycobacteria might possess either direct antitumor effects or tumor suppressor properties.

BCG vaccine has been the "standard of care for patients with bladder cancer (NMIBC)" since 1977. The antitumor effect of BCG is not cytotoxic in nature but rather a multifaceted and sustained activation of the local immune system. Historically, immunotherapy in bladder cancer was limited to local intravesical therapy with BCG vaccine for patients with nonmuscle invasive bladder cancer. BCG was then investigated as a potential immunotherapy in multiple cancers but had not demonstrated consistent results. In urothelial carcinoma, however, the role of BCG was confirmed with two early randomized trials demonstrating a decrease in tumor recurrence in patients receiving intravesical BCG.

IFNα has been extensively studied in combination with BCG for the treatment of superficial bladder cancers. As the helper T cell-1 (Th1) response in the bladder is critical to BCG efficacy, the rationale for this combination rests in the enhanced Th1 stimulation with IFNα, which can augment the immune response to BCG. Patients with BCG-refractory disease or post-BCG relapse may potentially benefit from the addition of IFNα to BCG, though many of these patients are considered for cystectomy to prevent progression of the disease.

BCG in Renal Cancer

Metastatic RCC has proved to be most recalcitrant to treatment, but with the advent of effective kinase inhibiters such as sunitinib and timsirolimus, further study of adjuvant BCG could prove beneficial.

BCG in Prostate Cancer

Direct injection of BCG into adenocarcinoma of the prostate in men induces a granulomatous response associated with tumor necrosis, but such approaches have been abandoned because of the risk of fatal septic reactions. Animal model studies have confirmed that BCG inhibits the growth of prostate cancer.

Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.